Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Dercum's Disease: What It Is and Can CBL-514 Fix It?

Dercum's disease is a rare condition in which the fatty tissue just under the skin is painful, often with many lumps called lipomas that are not cancer. Its cause is unknown, there is no lab test for it, and NORD says no specific treatment exists.

Can CBL-514 fix it? Not as far as any study has shown. CBL-514 is an experimental drug that has been tried in two small trials in people with Dercum's lumps, and its maker, Caliway, says no country has approved it for any use.

Below, we explain the disease first: how it feels, who it affects and how doctors recognize it. Then we look at what those trials measured, what Fast Track and orphan status do and do not mean, and what would still have to happen before anyone could say the drug works. The facts were checked on 20 November 2026.

On this page

Can CBL-514 fix Dercum's disease?

No study has shown that it can. The two trials so far were small, with 12 and 19 people, and they tracked lump size and pain through 8 weeks in the first trial and pain at week 20 in the second. In our reading, that is a long way from showing a drug fixes a disease. The only result against a placebo comes from the company's press release; no paper or registry results are available for outside review.

CBL-514 also has no approval. Caliway, the company behind it, stated on 30 October 2026 that it remains investigational and is not approved for sale in any country. NORD says no specific treatment for Dercum's disease exists at all.

Where CBL-514 stands for Dercum's disease, from trial registries, one paper, FDA and EU records and Caliway, checked 20 November 2026.
QuestionAnswer
Approved for Dercum disease?No. On 30 October 2026, Caliway said CBL-514 was not approved for sale in any country or jurisdiction
Human trials in Dercum diseaseTwo, both Phase 2 and completed, with 12 and 19 people
What they measuredLump size and pain at 8 weeks in the first trial; pain at week 20 in the second
Placebo-controlled resultReported by the company in a press release; no peer-reviewed paper or registry results yet
Phase 3 trial in Dercum diseaseNone found on ClinicalTrials.gov, 20 November 2026
Official designationsFDA and EU orphan designations for a Caliway product, and Fast Track per the company; none is an approval

Sources: Caliway statement, 30 Oct 2026; ClinicalTrials.gov NCT05387733; Phase 2a research letter, JAAD International, 2026 (PMC12854054); ClinicalTrials.gov NCT06303570; Caliway news release, 21 Sep 2026 (company claim); ClinicalTrials.gov search for CBL-514; FDA orphan drug database record; EU register of orphan medicines; Caliway news release, 15 Feb 2024 (company claim); NORD report on Dercum's disease (updated 26 Mar 2020)

What is Dercum's disease?

It is a rare disorder of painful fat just under the skin, also called adiposis dolorosa. Most of its key facts fit in eight rows from NIH and NORD.

Dercum's disease at a glance, from NIH MedlinePlus, NORD and two reviews, checked 20 November 2026.
PointWhat sources say
Other nameAdiposis dolorosa
What it isPainful fatty tissue just under the skin, often with many noncancerous lumps called lipomas
Most often seen inWomen aged 35 to 50 who are overweight or have obesity
How commonBelieved to be rare; the exact number is unknown
CauseUnknown
Lab testNone. Doctors decide from an exam after ruling out look-alike conditions
Specific treatmentNone exists, per NORD; care aims at symptoms, mainly pain
Approved drug for itNone found in the US as of 20 November 2026

Sources: NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); NORD report on Dercum's disease (updated 26 Mar 2020); Hansson and colleagues, review, 2012 (PMC3444313); FDA orphan drug database record

What are the symptoms of Dercum's disease?

The main symptom is pain in fatty tissue. NIH MedlinePlus says the lipomas usually feel like firm bumps under the skin and tend to hurt. The pain can be severe, especially when a lump presses on a nearby nerve, and for some people it is disabling.

The lumps can grow anywhere, but they show up most often on the torso, the buttocks, and the upper arms and legs. NORD says they are rare on the head, neck, hands and feet, and can be as small as a pea or as big as a fist.

In a 2012 review, patients most often called the pain burning or aching. The authors describe it as lasting longer than three months, on both sides of the body, often disabling, and hard to ease with standard painkillers. NORD says the pain can range from mild discomfort when a lump is pressed to pain far worse than what can be seen, and some people feel that all of their fat hurts.

NORD also lists other problems some people report, such as tiredness, weakness, easy bruising and trouble with memory or focus. MedlinePlus notes that these do not happen in everyone, and it is not clear whether they come from the disease itself.

One odd fact stands out. Under a microscope, a 2019 review says most reports find the lumps look just like ordinary lipomas, with no signs of inflammation. One report did find more connective tissue, so "the same" means mostly the same. The 2012 authors also suggested four forms, from widespread painful fat with no clear lumps to single fat pads near joints like the inner knee. That is their proposal, not an agreed standard.

Sources: NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); NORD report on Dercum's disease (updated 26 Mar 2020); Hansson and colleagues, review, 2012 (PMC3444313); Kucharz and colleagues, review, 2019 (PMC6911249)

Who gets Dercum's disease, and how common is it?

MedlinePlus says it shows up most often in women between 35 and 50 who are overweight or have obesity. The 2012 review reports it as five to thirty times more common in women than in men. NORD adds that it has been seen in children, but only very rarely.

How many people have it is unknown. It is thought to be rare, but no source we checked gives a number, and NORD says it is underdiagnosed, which makes the true count hard to find. Most cases happen with no family history. In the few families with several affected members, MedlinePlus says it seems to pass down in a pattern doctors call autosomal dominant. Even so, no gene has been found.

Sources: NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); Hansson and colleagues, review, 2012 (PMC3444313); NORD report on Dercum's disease (updated 26 Mar 2020)

Where does the name Dercum's disease come from?

From a doctor. Francis Xavier Dercum was a neurologist in Philadelphia. A 2019 review says he published papers on the condition in 1888 and 1892, and he used the term adiposis dolorosa, which is still its second medical name. Some sources give an earlier year, but we follow the dates of the papers themselves as the review lists them.

Other names in the medical literature include Morbus Dercum, adiposalgia, lipomatosis dolorosa and adipose tissue rheumatism. More than a century after Dercum, the cause is still unknown.

Sources: Kucharz and colleagues, review, 2019 (PMC6911249); Hansson and colleagues, review, 2012 (PMC3444313); NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); NORD report on Dercum's disease (updated 26 Mar 2020)

What causes Dercum's disease?

No one knows. MedlinePlus lists ideas that have been suggested: infections, inflammation, traumatic events, changes in how the body stores and breaks down fat, and changes in the nervous, immune or hormone systems. None of them has been confirmed.

One long-standing idea is that growing fatty masses stretch or press on nerves, and that this causes the pain. The 2012 review says that theory has never been confirmed under the microscope. So both questions, why it starts and why the fat hurts, remain open.

Sources: NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); Hansson and colleagues, review, 2012 (PMC3444313)

How do doctors diagnose Dercum's disease?

With an exam, because there is no lab test. The 2012 review says no laboratory markers exist, and blood tests for inflammation and autoimmune disease usually come back negative. The diagnosis rests on a careful physical exam and on ruling out other conditions first.

Conditions the review says doctors rule out include fibromyalgia, lipedema, hormone disorders, other conditions with many lipomas, and fat tissue tumors. NORD describes the usual path as a detailed history, a clinical exam and finding the typical lumps. A biopsy can confirm that the lumps are lipomas, though it does not prove Dercum's disease on its own.

Even the rules are unsettled. The 2012 review says its proposed diagnostic criteria have never been validated, and a 2019 review says the classification, the criteria and the treatment approach are still debated. Only a doctor who examines a person can judge any of this; this page cannot.

Sources: Hansson and colleagues, review, 2012 (PMC3444313); NORD report on Dercum's disease (updated 26 Mar 2020); Kucharz and colleagues, review, 2019 (PMC6911249)

Is there a treatment for Dercum's disease?

Not a specific one. NORD says no specific treatment exists, and care is aimed at each person's symptoms, mostly easing the painful episodes. A 2019 review says there is no generally accepted way to manage it.

The reviews describe what has been reported in the literature, not what anyone should do. Some approaches helped in single case reports, but the 2019 review says most rest on anecdotes and were never confirmed in clinical trials, and the 2012 review says none has given long lasting, complete pain relief. Choices about care belong to a patient and their own doctor.

Over time, the picture is mixed. In a study with five years of follow-up, cited by the 2012 review, average pain stayed about the same, while some people had less pain and some had more.

Sources: NORD report on Dercum's disease (updated 26 Mar 2020); Kucharz and colleagues, review, 2019 (PMC6911249); Hansson and colleagues, review, 2012 (PMC3444313)

What did the Dercum's trials of CBL-514 measure and find?

Two small Caliway trials measured lump size and pain, and both reported drops. In our reading, those measures cannot show whether the disease goes away. Caliway funded the first and announced the results of the second. The company describes CBL-514 as an investigational drug designed to reduce fat at the spot where it is given. How it works, and its trials for other uses, are on our CBL-514 page, so here we cover only the Dercum's work.

The two completed CBL-514 trials in Dercum's lipomas, from ClinicalTrials.gov, one research letter and one company release.
PointFirst trial (NCT05387733)Second trial (NCT06303570)
DesignPhase 2a, open label, no placebo group, no blindingPhase 2, saline placebo, planned 1 to 1 split (actual group sizes not published), only participants blinded
Who and where12 adults, mean age 52.5, 83.3 percent women; one site in Tucson, US; October 2022 to April 202319 people enrolled (about 25 planned); one site in Spokane, US; finished 14 April 2026
What it measuredSize of the treated lumps, and pain on a 0 to 10 scale, up to 8 weeksMain measure: pain score at week 20
What was reportedMedian lump volume down about 45 percent in one group and 51 percent in the other at 8 weeks, counted per lump across 77 lumps; median pain score down 4 pointsCompany figures: average pain down 3.1 points with CBL-514 and 1.9 with placebo at week 20
Where the result comes fromPeer-reviewed research letter, JAAD International, 2026Press release only; no paper and no registry results as of 20 November 2026
Adverse eventsEveryone had at least one, mostly mild to moderate reactions at the treatment site; none serious or fatal; 4 people had severe events and 2 left the studyCompany says no drug-related serious adverse events; no safety tables published
Ties to the companyCaliway paid for the study and the writing; three of five authors are Caliway staff who hold sharesCaliway trial code CBL-0202DD; results so far only from Caliway

Why these numbers fall short of proof: the first trial had no comparison group, so it cannot tell a drug effect from a placebo effect, and its own authors name the small sample, the missing comparator and the short follow-up as limits. In the second trial, only the participants were blinded, so the staff giving treatment knew who got what. Its placebo group improved too, by 1.9 points, and no paper or registry results are available for outside review. These are small-trial results, not promises.

CBL-514 is not the only compound tried. Another experimental drug, RZL-012 from Raziel Therapeutics, finished a double-blind, placebo-controlled Phase 2b trial in 38 people with Dercum's lumps in 2021. It is not approved for Dercum's disease either. For a rare-condition medicine in this series that did reach FDA approval, see our Imcivree page.

Sources: ClinicalTrials.gov NCT05387733; Phase 2a research letter, JAAD International, 2026 (PMC12854054); ClinicalTrials.gov NCT06303570; Caliway news release, 21 Sep 2026 (company claim); ClinicalTrials.gov NCT04229030

What do Fast Track and orphan status mean for CBL-514?

They are steps in the drug development process, not proof that it works. None of the three is an approval, and none is a trial result. Orphan status is tied to a rare disease, and the FDA describes Fast Track as meant for serious conditions with an unmet need.

Two orphan designations in FDA and EU records, plus a Fast Track designation Caliway reports, and what each one does and does not mean, checked 20 November 2026.
LabelRecordWhat it isWhat it is not
FDA orphan drug designationFDA database: a Caliway product, designated 27 February 2024; the record does not use the name CBL-514A status for a product aimed at a rare disease. The FDA says it is a separate process from approvalAn approval. The record reads Not FDA Approved for Orphan Indication
EU orphan designationEuropean Commission register: EU/3/24/2995, listed as curcumin and resveratrol, Caliway, 11 November 2024An entry in the EU register of orphan medicinesAn approval to sell the medicine in the EU
FDA Fast TrackCaliway release, 15 February 2024. The FDA keeps no public Fast Track list, so this rests on the companyPer the FDA, a process to help develop, and speed the review of, drugs for serious conditions with an unmet needAn approval, or a trial result

Two details matter. The FDA and EU records name a Caliway product, not CBL-514 by name; the link to CBL-514 comes from Caliway's own releases. And the FDA says drugs for rare diseases still go through the same rigorous scientific review as any other drug before approval, so orphan status is no shortcut around the evidence.

Sources: FDA orphan drug database record; FDA, designating orphan products; EU register of orphan medicines; Caliway news release, 15 Feb 2024 (company claim); FDA, Fast Track explained

What is still unknown about Dercum's disease and CBL-514?

Much more is unknown than known, for the disease and for the drug. This table sorts each big question by how settled it is, so you can see where the evidence stops.

Settled or open: the main questions about Dercum's disease and CBL-514, from NIH, NORD, two reviews, FDA records and ClinicalTrials.gov, checked 20 November 2026.
QuestionStatusWhat the sources say
What it looks and feels likeDescribedPainful fat under the skin, often with firm lipomas on the trunk, buttocks, upper arms and upper legs
How many people have itUnknownNo prevalence figure exists, and NORD says it is underdiagnosed
What causes itUnknownSeveral ideas suggested, none confirmed; no gene found
Why the fat hurtsUnknownThe nerve pressure idea was never confirmed under the microscope
A lab or blood testNone existsNo laboratory markers; inflammation and autoimmune blood tests usually come back normal
Agreed diagnostic rulesNot settledProposed criteria were never validated, and a 2019 review says experts still debate them
A specific treatmentNoneNORD says care is aimed at symptoms, mainly easing pain
An approved drug for itNone foundThe FDA orphan record for a Caliway product reads not approved
Whether CBL-514 beats placeboNot checkable yetOnly a company press release reports the placebo trial; no paper and no registry results as of 20 November 2026
What CBL-514 does over the long runUnknownThe first trial followed people for 8 weeks, and its authors list the short follow-up as a limit
A Phase 3 trial in Dercum diseaseNone foundClinicalTrials.gov lists none for CBL-514 in Dercum disease; its Phase 3 trials are for fat under the skin

Sources: NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); NORD report on Dercum's disease (updated 26 Mar 2020); Hansson and colleagues, review, 2012 (PMC3444313); Kucharz and colleagues, review, 2019 (PMC6911249); FDA orphan drug database record; Phase 2a research letter, JAAD International, 2026 (PMC12854054); Caliway news release, 21 Sep 2026 (company claim); ClinicalTrials.gov search for CBL-514

What would have to happen before anyone could say CBL-514 works?

More evidence that others can check. Going by the gaps the sources themselves name, these steps are still missing before the evidence could support that claim, and approval is a separate step on top:

  • The placebo trial's full results would need to appear in a peer-reviewed paper or on ClinicalTrials.gov, so outside experts can check the 3.1 versus 1.9 point claim. As of 20 November 2026, neither exists.
  • The limits the first trial's authors named, a small sample, no comparison group and a short follow-up, would need answers from studies with more people, a placebo group and a longer watch period.
  • A later-stage trial in Dercum's disease would need to be registered and finished. We found no Phase 3 trial of CBL-514 for Dercum's disease, and no public plan or timing for one.
  • Approval is a separate, regulatory step. The FDA says drugs for rare diseases go through the same rigorous scientific review as any other drug. Caliway itself says CBL-514 has no approval for sale in any country.

Until then, the honest answer to whether CBL-514 can fix Dercum's disease is that nobody knows. We re-read the FDA, EU and trial records on 20 November 2026, the check set out in our medical review policy.

Sources: Caliway news release, 21 Sep 2026 (company claim); ClinicalTrials.gov NCT06303570; Phase 2a research letter, JAAD International, 2026 (PMC12854054); ClinicalTrials.gov search for CBL-514; FDA, designating orphan products; Caliway statement, 30 Oct 2026

What else do people ask about Dercum's disease?

What is Dercum's disease in simple words?+

It is a rare condition where the fat just under the skin hurts. Many people with it have several firm, noncancerous lumps called lipomas, and the pain can be severe. Its other medical name is adiposis dolorosa.

Can CBL-514 fix Dercum's disease?+

No study has shown that it can. It has been tried in two small Phase 2 trials, of 12 and 19 people, which tracked lump size and pain through 8 weeks in the first and pain at week 20 in the second. The result against placebo comes only from a company press release, and Caliway says no country has approved CBL-514 for any use.

Does Fast Track or orphan status mean a drug works?+

No. The FDA says orphan designation is a separate process from approval, and Fast Track is a process meant to speed development and review for serious conditions with an unmet need. Neither one is a trial result.

What causes Dercum's disease?+

Nobody knows yet. NIH MedlinePlus lists suggested causes such as infections, inflammation, traumatic events and changes in how fat is stored and broken down, but none has been confirmed. A few families have more than one affected member, yet no genetic cause has been found.

Is Dercum's disease the same as lipedema?+

No. A 2012 review lists lipedema (spelled lipoedema there) among the conditions doctors rule out before they make a Dercum's diagnosis, along with fibromyalgia and other lipoma conditions.

How is Dercum's disease diagnosed?+

By a doctor's exam, not a lab test. Reviews say there are no laboratory markers, so the diagnosis rests on the patient's history, a physical exam and ruling out conditions that look similar. A biopsy can confirm that a lump is a lipoma, but it cannot confirm Dercum's disease itself.

Is there a treatment for Dercum's disease?+

NORD says no specific treatment exists. Care is aimed at the symptoms, mainly the pain, and is decided between a patient and their own doctor. This page does not recommend any treatment.

Is CBL-514 approved anywhere?+

No. Its maker, Caliway, said on 30 October 2026 that CBL-514 is still investigational and that no country has approved it for sale. The FDA orphan record for a Caliway product in Dercum disease also reads not approved.

Is Dercum's disease cancer?+

No. MedlinePlus describes the lipomas as noncancerous (benign) growths, and a 2019 review says most reports find them indistinguishable from ordinary lipomas under the microscope.

Sources: NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); NORD report on Dercum's disease (updated 26 Mar 2020); Hansson and colleagues, review, 2012 (PMC3444313); Kucharz and colleagues, review, 2019 (PMC6911249); Caliway statement, 30 Oct 2026; Caliway news release, 21 Sep 2026 (company claim); FDA, designating orphan products; FDA, Fast Track explained

What did we learn about Dercum's disease?

The takeaway: Dercum's disease is painful fat under the skin, often with lipomas, and its cause, its true frequency and why it hurts are all still unknown. NORD says no specific treatment exists. Can CBL-514 fix it? No study has shown that. Two small trials reported less pain and smaller lumps, one of them only through a company release, and Caliway says no country has approved the drug.

Each Molecule Mechanics episode is a short animated explainer, and this written version leans on NIH MedlinePlus, NORD, two peer-reviewed reviews, ClinicalTrials.gov, one trial paper, FDA and EU records and the company's own releases, as of 20 November 2026.

Spotted an error about Dercum's disease on this page? Our corrections policy shows the way to report it, and we fix sourced mistakes.

Sources: NIH MedlinePlus, adiposis dolorosa (updated 12 Feb 2026); NORD report on Dercum's disease (updated 26 Mar 2020); Phase 2a research letter, JAAD International, 2026 (PMC12854054); Caliway news release, 21 Sep 2026 (company claim); Caliway statement, 30 Oct 2026

A note on use: this page describes a rare condition for learning only. Every fact traces to NIH, NORD, peer-reviewed papers, trial registries or FDA and EU records, listed at the end of its section. Nothing here diagnoses anyone or points to a treatment; questions about your own health belong with a licensed clinician.

Sources

  1. 1.NIH MedlinePlus Genetics, adiposis dolorosa, read 20 November 2026 (page updated 12 February 2026): painful fatty tissue just under the skin, often with multiple noncancerous lipomas; lipomas feel like firm bumps, often on the torso, buttocks, upper arms and legs; pain can be severe and in some people disabling; most often in women aged 35 to 50 who are overweight or have obesity; believed to be rare, exact prevalence unknown; cause unknown, no genetic cause found; suggested causes are unconfirmed; most cases are sporadic; other reported features may not be directly related.
  2. 2.NORD (National Organization for Rare Disorders), Dercum's disease report, read 20 November 2026 (last updated 26 March 2020): a rare disorder with multiple painful fatty growths; lipomas from pea size to fist size, rare in the head, neck, hands and feet; some people feel that all fat hurts; underdiagnosed, very rarely reported in children; diagnosis by history, exam and the typical lipomas, with a biopsy confirming lipoma tissue; no specific treatment exists, care aims at symptoms, mainly pain.
  3. 3.Hansson and colleagues, review, 2012, PMC3444313: other names in the literature; pain most often burning or aching, chronic (over 3 months), symmetrical, often disabling; most common between 35 and 50, five to thirty times more common in women; proposed four forms; nerve pressure idea never confirmed under the microscope; clinical diagnosis after excluding look-alike conditions; no laboratory markers; diagnostic criteria never validated; no treatment has given long lasting complete pain relief; a study with five year follow-up found average pain roughly constant.
  4. 4.Kucharz and colleagues, review, 2019, PMC6911249: Francis Xavier Dercum, a Philadelphia neurologist, published papers in 1888 and 1892 and used the term adiposis dolorosa; most reports find the fat masses indistinguishable from lipomas, without inflammation; no generally accepted management; classification, diagnostic criteria and treatment strategy remain debated.
  5. 5.ClinicalTrials.gov NCT05387733, read 20 November 2026: open-label, randomized Phase 2a CBL-514 study in Dercum disease lipomas; 12 participants at one US site; October 2022 to April 2023; completed; no placebo group, no blinding; no results posted.
  6. 6.Phase 2a research letter, JAAD International, 2026, PMC12854054 (DOI 10.1016/j.jdin.2025.11.022): 12 adults, mean age 52.5, 83.3% female; median treated lipoma volume fell about 45% and 51% in the two groups at 8 weeks, against each lipoma at the start; median pain score fell 4.0 points at 4 weeks and held at 8 weeks; every participant had at least one treatment-related adverse event, mostly mild to moderate site reactions; none serious or fatal; 4 severe; 2 discontinued. Authors list small sample, no comparator and short follow-up. Funded by Caliway; three of five authors are Caliway employees who hold shares.
  7. 7.ClinicalTrials.gov NCT06303570, read 20 November 2026: single-blind, placebo-controlled, randomized Phase 2 study of CBL-514 in Dercum disease lipomas; 19 enrolled; main outcome pain at week 20; completed 14 April 2026; no results posted (record updated 22 September 2026).
  8. 8.Caliway news release, 21 September 2026, read 20 November 2026: company says the Phase 2 trial met its main goal, with mean pain scores down 3.1 points on CBL-514 and 1.9 on placebo at week 20; no drug-related serious adverse events reported; no approved therapies specifically for Dercum disease; cause and biology incompletely understood. Company claim, not peer reviewed.
  9. 9.Caliway news release, 15 February 2024: company says the FDA granted Fast Track designation for the investigation of CBL-514 in Dercum disease. FDA does not publish a public Fast Track list, so this stays a company claim.
  10. 10.FDA, Fast Track: a process to help develop, and speed the review of, drugs for serious conditions with an unmet need. It is not an approval.
  11. 11.FDA orphan drug database, read 20 November 2026: a Caliway Biopharmaceuticals product designated 27 February 2024 for treatment of patients with Dercum's disease (adiposis dolorosa); status: not FDA approved for the orphan indication. The record does not use the name CBL-514.
  12. 12.FDA, designating orphan products: orphan designation is a separate process from approval, and rare disease drugs go through the same scientific review as any other drug.
  13. 13.European Commission, Community Register of orphan medicinal products: EU/3/24/2995, curcumin and resveratrol, Caliway Biopharmaceuticals Czech s.r.o., treatment of Dercum disease, designated 11 November 2024. A designation is not an approval.
  14. 14.ClinicalTrials.gov search for CBL-514, 20 November 2026: 16 studies; only NCT05387733 and NCT06303570 list Dercum disease, both Phase 2 and completed; the Phase 3 records are for fat under the skin.
  15. 15.Caliway statement, 30 October 2026: CBL-514 is still an investigational candidate, with no marketing approval granted in any country or jurisdiction.
  16. 16.ClinicalTrials.gov NCT04229030, read 20 November 2026: double-blind, placebo-controlled Phase 2b trial of RZL-012 (Raziel Therapeutics) in 38 people with Dercum disease lipomas, completed February 2021, results posted on the registry.